GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (FRA:CUL) » Definitions » Total Assets

Aspira Womens Health (FRA:CUL) Total Assets : €6.59 Mil (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Aspira Womens Health Total Assets?

Aspira Womens Health's Total Assets for the quarter that ended in Mar. 2024 was €6.59 Mil.

Warning Sign:

If a company builds assets at 15.8% a year, faster than its revenue growth rate of 9.7% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Aspira Womens Health's average Total Assets Growth Rate was -5.30% per year. During the past 3 years, the average Total Assets Growth Rate was 7.20% per year. During the past 5 years, the average Total Assets Growth Rate was 15.80% per year. During the past 10 years, the average Total Assets Growth Rate was 12.00% per year.

During the past 13 years, Aspira Womens Health's highest 3-Year average Total Assets Growth Rate was 127.70%. The lowest was -61.70%. And the median was 0.40%.

Total Assets is connected with ROA %. Aspira Womens Health's annualized ROA % for the quarter that ended in Mar. 2024 was -276.27%. Total Assets is also linked to Revenue through Asset Turnover. Aspira Womens Health's Asset Turnover for the quarter that ended in Mar. 2024 was 0.32.


Aspira Womens Health Total Assets Historical Data

The historical data trend for Aspira Womens Health's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Total Assets Chart

Aspira Womens Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.45 16.12 36.36 16.40 5.74

Aspira Womens Health Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.74 7.13 8.12 5.74 6.59

Aspira Womens Health Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Aspira Womens Health's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=-2.169+7.911
=5.74

Aspira Womens Health's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=-1.254+7.845
=6.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aspira Womens Health  (FRA:CUL) Total Assets Explanation

Total Assets is connected with ROA %.

Aspira Womens Health's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-17.036/( (5.742+6.591)/ 2 )
=-17.036/6.1665
=-276.27 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Aspira Womens Health's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=1.981/( (5.742+6.591)/ 2 )
=1.981/6.1665
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Aspira Womens Health Total Assets Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspira Womens Health (FRA:CUL) Business Description

Traded in Other Exchanges
Address
12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Aspira Womens Health (FRA:CUL) Headlines

No Headlines